Oscar Gruss Launches Biotool Brief
THURSDAY, JUNE 29, 2000 12:14 PM
NEW YORK, Jun 29, 2000 /PRNewswire via COMTEX/ -- Oscar Gruss & Son Incorporated is launching a new research product, the BioTool Brief. The BioTool Brief is a weekly roundup and commentary on the broad universe of biotech tool suppliers, informatics companies and diversified genomics companies. This week's report includes news highlights of the week, the Chart of the Week, and weekly price performance information. Currently there are 33 companies tracked by the report.
About the Analyst: Jason Reed is a Vice President and Biotechnology Analyst. Jason holds a Ph.D. in Biomolecular Chemistry and an A.B. with concentration in Physics, and has special expertise in the area of genomics instrumentation and software. Jason is the author of multiple publications and patents in the fields of biotechnology and engineering.
The current tracking universe includes:
Millennium Pharmaceuticals, Inc.
Human Genome Sciences, Inc.
Myriad Genetics, Inc.
Genome Therapeutics Corp.
Axys Pharmaceuticals Inc.
Aclara BioSciences, Inc.
Aurora Biosciences Corp.
Caliper Technologies Corp.
Lexicon Genetics Inc.
Molecular Devices Corp.
Visible Genetics, Inc.
Lynx Therapeutics, Inc.
LJL Biosystems, Inc.
Incyte Genomics, Inc.
Gene Logic, Inc.
Rosetta Inpharmatics, Inc.
Clients of Oscar Gruss wishing to get a copy of this report should contact their broker.
This report is based upon information which Oscar Gruss & Son Incorporated (Oscar Gruss) believes to be reliable. However, neither Oscar Gruss nor any individual acting on the behalf of Oscar Gruss can guarantee the accuracy or completeness of its contents. It does not purport to contain a complete analysis of every material fact concerning any company, industry or security, and further information is available upon request. Oscar Gruss assumes that it will be read in conjunction with other available reports and data. Opinions expressed herein are subject to change without notice. No investor can assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Oscar Gruss makes a market in this security, and may have a long or short position in this security. Oscar Gruss and/or our employees and affiliates may have positions in securities which are referred to herein and may make purchases or sales thereof while this report is in circulation. Oscar Gruss or one of its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from a company mentioned in this report. Foreign-currency-denominated securities are subject to fluctuations in currency exchange rates that could have a positive or adverse effect on an investor's return upon the conversion into local currency of dividends or interest received, or proceeds from the sale of such securities. In addition, the value of U.S. dollar-denominated ADRs and the value of U.S. dollar- denominated ordinary shares, or common shares, of foreign issuers can be influenced by fluctuations in currency exchange rates.
SOURCE Oscar Gruss & Son Inc.